225Ac-CONV-01-α is an alpha-radiolabeled monoclonal antibody targeting PSMA developed for the treatment of metastasized prostate cancer patients. This product is developed by Convergent Therapeutics, a partner of Aikido Pharma. The drug entered Phase I/II trial.

Target/Mechanism: PSMA

Carrier/Ligand: CONV-01-α

Radiation Type: alpha particle (α)

< Back